Coherus BioSciences, Inc. (CHRS)
$
0.88
+0.01 (1.14%)
Key metrics
Financial statements
Free cash flow per share
0.0043
Market cap
102 Million
Price to sales ratio
0.5166
Debt to equity
-1.2614
Current ratio
1.2162
Income quality
-0.0038
Average inventory
36.8 Million
ROE
1.0743
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Coherus BioSciences, Inc. is a biopharmaceutical company that primarily targets the biosimilar and immuno-oncology markets in the United States. The company reported depreciation and amortization expenses of $5,276,000.00 reflecting the wear and tear of its assets. Its operating income ratio is -0.42 indicating the company's operational profitability margin. With a gross profit standing at $149,407,000.00 the company highlights its profitability from core operations. The weighted average number of shares outstanding is 114,553,537.00 shedding light on the company's shareholder base. Despite its efforts, the company reported a net loss of $28,507,000.00 indicating challenges in its operations. Coherus markets UDENYCA, a biosimilar to Neulasta, alongside a pipeline of products that include biosimilars for Humira, Avastin, and Lucentis. Additionally, the company is advancing the development of Toripalimab, a novel anti-PD-1 antibody for the second-line treatment of melanoma in China, as well as a Bevacizumab biosimilar and CHS-1420, an anti-TNF product candidate aiming to be an adalimumab biosimilar, along with a Ranibizumab biosimilar. Coherus holds license agreements with several prominent firms such as Selexis SA, AbbVie, Inc., Pfizer, Inc., Bioeq AG, Innovent Biologics (Suzhou) Co., Ltd., and Junshi Biosciences. Originally incorporated as BioGenerics, Inc., the company rebranded to Coherus BioSciences, Inc. in April 2012 and is headquartered in Redwood City, California. In the current market landscape, the stock is affordable at $0.87 which may attract budget-conscious investors. The stock has a high average trading volume of 1,503,783.00 indicating strong liquidity and interest from investors. With a market capitalization of $102,021,040.00 the company is classified as a small-cap player, positioning it uniquely within the industry. Coherus is a key player in the Biotechnology industry, contributing significantly to the overall market landscape, and it belongs to the Healthcare sector, driving innovation and growth. The company continues to focus on its mission to provide accessible biopharmaceutical solutions while navigating the complexities of the healthcare market.
Is Coherus BioSciences, Inc. (CHRS) a good investment?
Investing in Coherus BioSciences, Inc. (CHRS) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B-, with a Bullish outlook. Always conduct your own research before investing.
What is Coherus BioSciences, Inc. (CHRS)'s stock forecast?
Analysts predict Coherus BioSciences, Inc. stock to fluctuate between $0.66 (low) and $2.43 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Coherus BioSciences, Inc.'s market capitalization?
As of 2025-07-11, Coherus BioSciences, Inc.'s market cap is $102,021,040, based on 115,933,000 outstanding shares.
How does Coherus BioSciences, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Coherus BioSciences, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Coherus BioSciences, Inc. (CHRS) stock?
To buy Coherus BioSciences, Inc. (CHRS) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for CHRS. Place an order (Market, Limit, etc.).
What is the best time to invest in Coherus BioSciences, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
How did Coherus BioSciences, Inc. perform in the last earnings report?
Revenue: $266,960,000 | EPS: $0.25 | Growth: -109.88%.
Where can I find Coherus BioSciences, Inc.'s investor relations reports?
Visit https://www.coherus.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Coherus BioSciences, Inc.?
You can explore historical data from here
What is the all-time high and low for Coherus BioSciences, Inc. stock?
All-time high: $21.56 (2021-02-01) | All-time low: $0.66 (2024-11-05).
What are the key trends affecting Coherus BioSciences, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
seekingalpha.com
2 months ago
Coherus BioSciences, Inc. (NASDAQ:CHRS ) Q1 2025 Earnings Conference Call May 12, 2025 5:00 PM ET Company Participants Jodi Sievers - Head, Investor Relations Denny Lanfear - Chief Executive Officer Theresa LaVallee - Chief Scientific & Development Officer Rosh Dias - Chief Medical Officer Sameer Goregaoker - Executive Vice President, Commercial Bryan McMichael - Chief Financial Officer Conference Call Participants Kripa Devarakonda - Truist Securities Brian Cheng - JPMorgan Mike Nedelcovych - TD Cowen Colleen Kusy - Baird Douglas Tsao - H.C. Wainwright Operator Good day and thank you for standing by.
zacks.com
2 months ago
Coherus BioSciences (CHRS) came out with a quarterly loss of $0.35 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to loss of $0.32 per share a year ago.
globenewswire.com
2 months ago
– Strategic transformation to innovative oncology completed in Q2 2025 – – Positive CHS-114 (anti-CCR8 antibody) Phase 1b dose expansion study data in patients with head and neck cancer presented at 2025 AACR Annual Meeting – – Additional CHS-114 Phase 1b studies in 2L gastric cancer and 2L HNSCC ongoing – – Enrollment ongoing in the Phase 2 randomized trial of casdozokitug/toripalimab/bevacizumab in 1L HCC, with first data readout expected in 1H 2026 – – LOQTORZI net revenue was $7.3 million and UDENYCA net revenue, now reflected in discontinued operations, was $31.5 million in Q1 2025 – – Conference call today at 5:00 p.m. Eastern Time – REDWOOD CITY, Calif.
globenewswire.com
2 months ago
REDWOOD CITY, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that its first quarter 2025 financial results will be released after market close on Monday, May 12, 2025. Starting at 5:00 p.m. EDT on May 12, 2025, Coherus' management team will host a conference call and webcast to discuss financial results and provide a general business update.
globenewswire.com
2 months ago
REDWOOD CITY, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that the company will be webcasting its participation in the upcoming conferences:
globenewswire.com
3 months ago
– CHS-114 demonstrates clinical efficacy and proof of mechanism in HNSCC in combination with toripalimab – – Confirmed partial response in heavily pretreated PD-1 refractory patient supports expansion in HNSCC and gastric cancer in combination with toripalimab – – A second-line Phase 1 dose optimization study in HNSCC and gastric cancer is ongoing; results expected in the first half of 2026– – Coherus to host investor and analyst call with study investigator, Dr. Douglas Adkins, Washington University, today at 4:30 p.m. Eastern Time– REDWOOD CITY, Calif.
seekingalpha.com
3 months ago
Coherus BioSciences is now heavily focused on developing its pipeline, particularly casdozokitug and CHS-114, after shedding its marketed biosimilar drugs. Casdozokitug shows promise in metastatic hepatocellular carcinoma with a 17.2% complete response rate in phase 1 and is now in a phase 2 study. CHRS is still marketing Loqtorzi for nasopharyngeal carcinoma, with Q4'24 revenues of $7.5M representing 29% growth over the prior quarter.
globenewswire.com
3 months ago
– $250 million post-close cash balance extends cash runway over two years into 2027, funding pipeline development through key data catalysts –
globenewswire.com
4 months ago
REDWOOD CITY, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS), a commercial-stage innovative oncology company, today announced that an abstract highlighting interim data from its ongoing Phase 1 clinical trial evaluating CHS-114, a selective, cytolytic anti-CCR8 antibody, as monotherapy and in combination with toripalimab in patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC), has been selected for a poster presentation at the upcoming 2025 AACR Annual Meeting, being held April 25-30, 2025, at McCormick Place Convention Center in Chicago, Illinois.
seekingalpha.com
4 months ago
Coherus BioSciences, Inc. (NASDAQ:CHRS ) Q4 2024 Earnings Conference Call March 10, 2025 5:00 PM ET Company Participants Jodi Sievers - Head of IR Denny Lanfear - CEO Paul Reider - CCO Sameer Goregaoker - SVP, Immuno-Oncology Marketing Theresa LaVallee - CDO Rosh Dias - CMO Bryan McMichael - CFO Conference Call Participants Srikripa Devarakonda - Truist Securities Yigal Nochomovitz - Citigroup Colleen Kusy - Baird Michael Nedelcovych - TD Cowen Brian Cheng - JPMorgan Douglas Tsao - H.C. Wainwright Operator Hello everyone and welcome to the Coherus Fourth Quarter Year Ending 2024 Financial Results Conference call.
See all news
